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Background and Purpose—The prediction of genetic predispositions to ischemic stroke (IS) may allow the identification 
of individuals at elevated risk and thereby prevent IS in clinical practice. Previously developed weighted multilocus 
genetic risk scores showed limited predictive ability for IS. Here, we investigated the predictive ability of a newer method, 
polygenic risk score (polyGRS), based on the idea that a few strong signals, as well as several weaker signals, can be 
collectively informative to determine IS risk.
Methods—We genotyped 13 214 Japanese individuals with IS and 26 470 controls (derivation samples) and generated both 
multilocus genetic risk scores and polyGRS, using the same derivation data set. The predictive abilities of each scoring 
system were then assessed using 2 independent sets of Japanese samples (KyushuU and JPJM data sets).
Results—In both validation data sets, polyGRS was shown to be significantly associated with IS, but weighted multilocus 
genetic risk scores was not. Comparing the highest with the lowest polyGRS quintile, the odds ratios for IS were 1.75 
(95% confidence interval, 1.33–2.31) and 1.99 (95% confidence interval, 1.19–3.33) in the KyushuU and JPJM samples, 
respectively. Using the KyushuU samples, the addition of polyGRS to a nongenetic risk model resulted in a significant 
improvement of the predictive ability (net reclassification improvement=0.151; P<0.001).
Conclusions—The polyGRS was shown to be superior to weighted multilocus genetic risk scores as an IS prediction model. 
Thus, together with the nongenetic risk factors, polyGRS will provide valuable information for individual risk assessment 
and management of modifiable risk factors.   (Stroke. 2017;48:253-258. DOI: 10.1161/STROKEAHA.116.014506.)
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Ischemic stroke (IS) is a leading cause of death and long-term disability in the world.1 Although a large proportion of IS 
events could be prevented by appropriate management of modi-
fiable risk factors, such as high blood pressure and tobacco use,2 
the burden attributable to these modifiable risk factors remains 
problematic.3 To lower this burden, it is important to apply both 
population and high-risk approaches.4 Genetic information can 
be a useful tool for the identification of high-risk individuals.
The effects of individual genetic markers are relatively small 
for common polygenic disorders, and therefore, a well-studied 
approach, weighted multilocus genetic risk score (wGRS), typ-
ically integrates tens of weak genetic markers into a single risk 
score, based on summary statistics from genome-wide associa-
tion (GWA) studies.5 For hypertension and coronary artery dis-
ease, wGRSs have been derived from GWA data of the target 
traits.5 However, previous IS GWA studies have identified only 
a few replicable susceptibility loci,6–9 possibly because of the 
etiologic heterogeneity of IS. Therefore, wGRSs for IS in pre-
vious studies have been derived from GWA data on hyperten-
sion,10 atrial fibrillation,11 and coronary artery disease,12–14 and 
their predictive abilities have been limited.10–14
We hypothesized that the lower predictive abilities of 
wGRSs are related to the polygenic nature of IS. A previous 
analysis on international IS GWA data inferred that genetic 
predispositions to IS are shared among the different sub-
types,15 which may be related to susceptibilities to arterioscle-
rosis, hypertension, hyperlipidemia, and their combinations. 
Thus, we sought to develop a statistical model to predict the 
genetic predispositions shared among IS subtypes, rather than 
identify genetic markers specific to IS subtypes. To accom-
plish this, we created a polygenic risk score (polyGRS) based 
on the assumption that, in addition to a few genome-wide sig-
nals obtained from IS GWA data, numerous weaker signals 
can be collectively informative for predicting IS incidence. 
In previous studies, polyGRSs showed remarkable predictive 
abilities for schizophrenia, bipolar disorder, hypertension, and 
coronary artery disease.16,17 However, the predictive ability of 
polyGRS for IS remains to be determined. The complexity 
of IS subtypes requires the validation of the genetic model; 
therefore, we derived both a wGRS and polyGRS from the 
same large-scale derivation samples and compared their pre-
dictive abilities in 2 sets of independent samples.
Methods
Cohorts and Case Definition
In this study, we used 3 sets of Japanese samples. The first set (deriva-
tion data set) was used to derive a wGRS and polyGRS. The second 
set (KyushuU data set) was used to assess the predictive abilities of 
the 2 GRSs with detailed clinical information. The third set (JPJM 
data set) was used as an additional data set for the validation of the 
predictive abilities. All 3 sets of samples were independent from each 
other.
For the derivation data set, patients with IS were recruited by the 
BioBank Japan Project from 2003 to 2008.18 All participants provided 
written informed consent, as approved by the ethical committees of 
the BioBank Japan Project and the University of Tokyo. Clinical 
information on the subjects was collected from medical charts, neu-
roimaging results (including computed tomography and magnetic 
resonance imaging), and self-reported questionnaires. Controls in 
the derivation data set were enrolled from participants in Japanese 
prospective cohort studies, including the Tohoku Medical Megabank 
Project,19 the Japan Public Health Center–based prospective study,20 
and the Japan Multi-Institutional Collaborative Cohort Study.21 
Details of the study design and recruitment methods of the 3 cohort 
studies were described previously.19–21
For the KyushuU data set, details of the recruitment methods and 
diagnostic criteria were described previously.6,22 Briefly, affected 
individuals with IS were recruited from 7 hospitals affiliated with 
Kyushu University in 2004. For all cases, diagnoses of IS and its 
subtypes were made by stroke neurologists from the affiliated hos-
pitals by referencing clinical presentation and ancillary labora-
tory examinations—namely, cerebral angiography, brain imaging, 
echocardiography, and carotid duplex imaging. Participants in the 
Hisayama study were enrolled as control subjects. The Hisayama 
study is a population-based cohort study established in 1961.23,24 
Of 3328 Hisayama residents aged ≥40 years who consented to par-
ticipate in the Hisayama study between 2002 and 2003, we selected 
age-matched (within 5 years) and sex-matched control subjects by 
1:1 matching using random numbers, after excluding subjects with 
a history of stroke or coronary heart disease. For the subjects in the 
KyushuU data set, hypertension was defined as systolic blood pres-
sure ≥140 mm Hg and diastolic blood pressure ≥90 mm Hg on at least 
3 different occasions or as current treatment with antihypertensive 
drugs.25 Diabetes mellitus was determined by a 75-g oral glucose tol-
erance test, casual blood glucose levels (>11.1 mmol/L), or a medical 
history of diabetes mellitus. Hyperlipidemia was defined as a total 
cholesterol level ≥5.69 mmol/L or current treatment with a choles-
terol-lowering drug. Atrial fibrillation was diagnosed based on elec-
trocardiographic findings.
For the JPJM data set, nested case–control subjects were enrolled 
from the participants of the Japan Public Health Center and Japan 
Multi-Institutional Collaborative Cohort studies in the Saga and 
Takashima regions.20,21,26 IS cases were confirmed by imaging stud-
ies, and age- and sex-matched controls were extracted from a pool of 
individuals with no history of stroke.27
Genotyping
All subjects from the 3 data sets were genotyped using a 
HumanOmniExpressExome BeadChip array (Illumina, Inc, San 
Diego, CA).
Quality Control Filters for Derivation Samples
Samples with low call rate (<0.98), single-nucleotide polymorphisms 
(SNPs) with low call rate (<0.99), and close relationships character-
ized by the identity-by-state method were excluded, as well as sub-
jects whose estimated ancestries outside of the Hondo cluster of the 
Japanese population28 by PCA.29,30 Variants with a Hardy–Weinberg 
equilibrium exact test P value of <1×10−6 and a minor allele frequency 
<0.01 were also excluded. Ultimately, 39 684 individuals (Table 1) 
with 537 999 autosomal SNPs were included in our analyses.
Genetic Risk Score Derivation
Our statistical analysis workflow is shown in Figure 1. The wGRS 
included 5 SNPs selected at the end of the replication and exploratory 
analyses from the derivation samples.
Additional quality control filters were applied to the derivation data 
set to generate the polyGRS: (1) samples with a call rate of <0.99, 
(2) SNPs with a Hardy–Weinberg equilibrium exact test P value of 
<0.05, (3) SNPs with a P value in the test for nonignorable difference 
between cases and controls of <0.05 were excluded, according to a 
previous study.31 Ultimately, no individuals were excluded by these 
filters, and 357 367 autosomal SNPs were retained.
According to a previous study,31 polyGRS by genotyped data 
shows higher predictive ability than the model using all imputed data. 
Therefore, we also used the genotyped variants (357 367 variants) to 
generate the polyGRS. As such, we used a dual-formula technique to 
minimize overfitting to the derivation data set. The polyGRS was gen-
erated via 2 models: (1) restricted maximum likelihood and (2) best 
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linear unbiased prediction. A mixed linear model was assumed in both 
cases,31 which accounts for genotype data via the genetic relationship 
matrix, leaving only the variances of genetic and nongenetic effects as 
free parameters. More specifically, the restricted maximum likelihood 
model estimates the 2 free parameters based on derivation samples 
(N=39 684), whereas the best linear unbiased prediction model con-
verts the variance parameter estimates into the weight parameters for 
the 357 367 SNPs in conjunction with the genotype data of deriva-
tion samples. In total, only 2 parameters were estimated through the 
restricted maximum likelihood and best linear unbiased prediction 
steps. Further details are provided in the online-only Data Supplement.
Predictive Ability Assessment
Because previous studies on wGRS typically evaluated the odds ratio 
(OR) of the highest score quintile versus the lowest score quintile,11,12 
we estimated the OR for each score quintile using Fisher exact test. In 
addition, the OR per 1 SD, the corresponding 95% confidence interval 
(CI), and the overall P value were estimated by the conditional logistic 
regression analysis. To compare the predictive abilities of the 2 GRSs, 
a continuous version of net reclassification improvement (NRI), an 
integrated discrimination improvement, and the C-index were calcu-
lated. The NRI, integrated discrimination improvement, and C-index 
were also calculated to assess the improvements in predictive ability 
obtained by adding the 2 GRSs to a nongenetic risk model.
Results
Derivation of Genetic Risk Scores
Of the 6 well-studied variants, the associations with IS 
were nominally significant regarding 4 variants (rs6843082 
[PITX2]; rs2383207 [CDKN2B-CDKN2A]; rs2107595 
[HDAC9]; and rs879324 [ZFHX3]) in our derivation samples 
(Tables I and II in the online-only Data Supplement).
For exploratory identification of IS-susceptibility loci, 
based on our derivation samples, the associations between 
6 204 347 imputed genetic variants and IS were subjected to 
a genome-wide analysis (Figure I and Table III in the online-
only Data Supplement). The results showed genome-wide 
significance (P<5×10–8) for one variant, rs1275923, which is 
located in an intron of KCNK3 (Figure II in the online-only 
Data Supplement) and is reportedly associated with blood 
pressure.32
Based on these results, we chose 5 variants as model 
variables for our wGRS (Table IV in the online-only Data 
Supplement). Additionally, from the same derivation data set, 
we created a polyGRS, based on the assumption that, in addi-
tion to several genome-wide signals, numerous weaker signals 
can be collectively informative for the prediction of IS inci-
dence. All genotyped variants that passed our quality control 
filters (357 367 variants) were used to derive the polyGRS.
Predictive Ability of Genetic Risk Scores
The predictive abilities of the wGRS and polyGRS were 
assessed using the KyushuU and JPJM samples. The power 
to detect significance with an OR of 1.2 per 1 SD was 99% 
and 66% for the KyushuU and JPJM data sets, respectively 
(Table 2). This was comparable to the OR of 1.17 per SD at 
PT=1 by the score-profiling model (Table V in the online-only 
Data Supplement), indicating that all genotyped variants in 
the polyGRS contributed useful signal to the score.
Although the polyGRS significantly associated with IS in 
both validation data sets, this was not observed with wGRS 
(Table 2). Moreover, the OR for the highest polyGRS quintile 
compared with the lowest polyGRS quintile was 1.75 (95% 
CI, 1.33–2.31) and 1.99 (95% CI, 1.19–3.33) in the KyushuU 
and JPJM samples, respectively (Figure 2), with a significant 
improvement observed in the KyushuU samples (NRI=0.179; 
Figure 3; Table VI in the online-only Data Supplement).
Predictive Ability of Genetic Risk 
Scores for Each Etiologic Subtype
In the KyushuU samples, the predictive abilities of the 2 
GRSs were investigated for each etiologic subtype: large-
vessel disease, small-vessel disease, and cardioembolic stroke 
(Figure 3). The wGRS failed to associate with any subtype, 
whereas the polyGRS was significantly associated with all 
3. Furthermore, the predictive ability of the subtype-mixture 
Table 1. Age and Sex Distributions of the Derivation, KyushuU, and JPJM Samples
Study design
Derivation KyushuU JPJM
Cases Controls Cases Controls Cases Controls
Case–Population Case–Control Nested Case–Control
Subjects 13 214 26 470 1097 1097 336 336
Age, y*, mean±SD 69±10 56±10 70±10 70±10 59±7 59±7
Women, % 35.7 60.6 39.1 39.1 37.5 37.5
*Age at enrollment.
Figure 1. Statistical analysis flow diagram. GWA indicates 
genome-wide association; IS, ischemic stroke; and SNP, single-
nucleotide polymorphism.
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polyGRS was higher than that of the subtype-specific model 
(Table VII in the online-only Data Supplement).
Integration of Genetic Risk Scores 
Into a Nongenetic Risk Model
Based on the KyushuU samples, the wGRS or polyGRS was 
added to a nongenetic risk model that included hypertension, 
diabetes mellitus, hyperlipidemia, and atrial fibrillation as 
model variables. Notably, the polyGRS showed an improved 
predictive ability, whereas the wGRS did not (Figure 4; Table 
VIII in the online-only Data Supplement). For all IS cases, 
the polyGRS NRI was estimated to be 0.151 (95% CI, 0.068–
0.235), the integrated discrimination improvement was 0.004 
(95% CI, 0.001–0.006), and the ∆C-index was 0.700 (95% 
CI, 0.679–0.722). When stratified by subtype, the NRI was 
significant for large-vessel disease and small-vessel disease 
but not cardioembolic stroke.
Discussion
Based on large-scale genotyping of Japanese samples (N>40 000 
in total), we showed that the polyGRS has a superior ability to 
predict IS compared with the wGRS. Given that the estimates of 
ORs of the highest score quintile compared with the lowest score 
quintile were at most ≈1.3 in previous studies,8–12 the higher OR 
for polyGRS (>1.75) indicated that the polygenic approach was 
well suited to derive genetic risk scores for IS. The difference 
in incident risk between the highest and lowest score quintiles 
(>75% difference)—which was consistently estimated from 
both retrospective (case–control) and prospective (nested case–
control) designs—supports the utility of polyGRS methodology 
for healthcare and preventive purposes. Moreover, the polyGRS 
significantly associated with all etiologic subtypes, suggesting 
that it effectively predicts the genetic predispositions shared 
among IS subtypes. Furthermore, the significant NRI estimates 
for all IS cases indicated that the integration polyGRS into non-
genetic risk models would be valuable, whereas the nonsignifi-
cant NRI for cardioembolic stroke suggested that the adjustment 
by atrial fibrillation and other nongenetic factors attenuated the 
predictive ability of the polyGRS.
One aspect of the clinical utility of the polyGRS is the indi-
vidualization of clinical criteria. Japanese clinical guidelines 
for the management of hypertension published in 2014 recom-
mended the grouping of patients with hypertension into risk 
strata based on blood pressure levels and other cardiovascular 
risk factors, including age, smoking, dyslipidemia, obesity, dia-
betes mellitus, and family history of young-onset cardiovascular 
disease.33 For each risk stratum, a distinct therapeutic strategy 
was recommended. Here, we showed that polyGRS may be a 
valuable predictor of IS. Accordingly, hypertensive patients 
whose risks have been underestimated without the additional 
genetic information would be reclassified into higher risk strata 
after including polyGRS as a part of the clinical criteria.
To advance further, prospective cohort studies on the pre-
dictive ability of the polyGRS would be essential. It would 
also be interesting to investigate whether the polyGRS derived 
from Japanese samples can predict IS in other East Asians and 
other ethnicities. Additionally, ethical, legal, social, and policy 
issues, including the responsibility for the management of the 
genetic information, should be discussed in future studies.
The difference between the predictive abilities of polyGRS 
and wGRS elucidates the polygenic nature of IS. An impor-
tant methodological difference between wGRS and polyGRS 
Table 2. Predictive Ability of the Multilocus and the Polygenic Risk Scores in the KyushuU and JPJM Samples
Validation 
Samples Model
Q1 OR  
(95% CI) Q2 OR (95% CI) Q3 OR (95% CI) Q4 OR (95% CI)
Q5 OR (95% 
CI)
OR per SD*  
(95% CI)
Overall* 
P Value
C-index  
(95% CI)
KyushuU
 (N=2194)
wGRS Reference 1.09 (0.83–1.43) 1.08 (0.82–1.42) 1.03 (0.78–1.35)
1.17  
(0.89–1.54)
1.04  
(0.96–1.14)
0.313
0.510  
(0.486–0.534)
polyGRS Reference 1.08 (0.82–1.42) 1.10 (0.84–1.45) 1.41 (1.08–1.86)†‡
1.75  
(1.33–2.31)†‡
1.20  
(1.10–1.31)†‡
<0.001‡
0.555  
(0.531–0.579)†‡
JPJM
(N=672)
wGRS Reference 1.37 (0.82–2.28) 2.02 (1.21–3.39)†‡ 1.39 (0.83–2.32)
1.45  
(0.87–2.42)
1.11  
(0.96–1.29)
0.172
0.530  
(0.487–0.574)
polyGRS Reference 1.96 (1.18–3.29)†‡ 1.69 (1.01–2.83)‡ 1.33 (0.80–2.23)
1.99  
(1.19–3.33)†‡
1.20  
(1.01–1.41)‡
0.033‡
0.536  
(0.492–0.580)
CI indicates confidence interval; OR, odds ratio; polyGRS, polygenic risk score; Q1–Q5, quantiles 1–5; and wGRS, weighted multilocus genetic risk score.
*Considering the genetic risk scores as continuous variables.
†Significant after multiple corrections.
‡Results are nominally significant (P<0.05).
Figure 2. Predictive ability of the 
weighted multilocus genetic risk scores 
(wGRS) and polygenic risk scores 
(polyGRS) in the (A) KyushuU and (B) 
JPJM samples. Odds ratio for each score 
quintile compared with the lowest score 
quintile. *Nominal significant odds ratios 
(P<0.05). **Significant odds ratios after 
multiple corrections.
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is that the wGRS only included 5 credible SNPs as model vari-
ables, whereas polyGRS used all genotyped SNPs. The supe-
rior predictive ability of polyGRS demonstrates the validity of 
our assumption that, in addition to a few genome-wide signals, 
numerous weaker signals are collectively informative for pre-
dicting IS. Furthermore, in the score-profiling model, the pre-
dictive ability improved as PT threshold increased. This result 
implies that usage of more SNPs is essential for improvement 
of the predictive ability. Our results suggest that a large num-
ber of IS-susceptibility loci with small effect size have yet 
to be discovered and that larger derivation and replication of 
GWA data sets would be advantageous for discovering novel 
susceptibility loci in future studies. Furthermore, given that 
we are currently unable to identify all IS-susceptibility vari-
ants with small effect size, polyGRS approach may represent a 
fascinating method to use the valuable information contained 
in weak GWA signals to predict IS.
Conclusions
We demonstrated that the polyGRS approach is superior 
to that of wGRS as a method of choice for the assessment 
of IS genetic risks. This is clinically important because the 
polyGRS approach is promising for the individualization of 
clinical criteria in the era of precision medicine.
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Supplementary Methods 
Genotype imputation for the derivation samples 
Genotype imputation was performed using MaCH1 and MiniMac22 software based on the 1000 
Genomes reference panel.3 After imputation, variants with an R2 < 0.5 and a MAF < 0.01 were 
excluded, resulting in 6,204,347 autosomal variants. 
 
Genome-wide association tests using derivation samples 
To investigate the associations of the 6,204,347 imputed variants with IS using derivation 
samples, P-values were calculated by a mixed linear model association (MLMA) method4 with 
age- and sex-adjustment. In comparison with principal component-based adjustment methods, 
the MLMA method has advantages for the adjustment of population structure in derivation 
samples.4 As expected, a quantile-quantile (QQ) plot showed that the inflation of the association 
P-values was well controlled in our genome-wide association tests (Supplementary Figure IV).  
Coefficients estimated from the MLMA method cannot be converted to odds ratios (ORs) 
because the interpretation of the coefficients of mixed linear models is similar to that of linear 
regression models, and is different from that of logistic regression models. Accordingly, we 
estimated ORs for the 6,204,347 variants by an additive effect model and a logistic regression 
analysis with age- and sex-adjustment. We did not adjust using principal components for the 
calculation of ORs.  
 
Imputation of genotypes for the validation samples  
The KyushuU and JPJM samples were genotyped at the Center for Integrative Medical Science 
(RIKEN) and at the Iwate Medical Megabank Organization (Iwate Medical University), 
respectively. Both samples were genotyped using a HumanOmniExpressExome BeadChip array. 
Samples with a call rate < 0.95 and SNPs with a call rate < 0.99 were excluded. Variants with 
a Hardy-Weinberg equilibrium exact test P-value < 1 × 10-6 and a minor allele frequency < 0.01 
were also excluded. 
Subsequently, we imputed genotypes of six SNPs included in our multi-locus genetic risk 
score. For each target SNP, genotyped SNPs within 500,000 base-pairs distance from the target 
SNP were extracted, and the target SNP was imputed by SHAPIT5 and Minimac32 software 
based on the 1000 Genomes reference panel.3 
 
Derivation of a multi-locus risk score  
A weighted multi-locus genetic risk score (wGRS) was calculated by multiplying the number of 
risk alleles for each SNP by the weight for that SNP, and then taking the sum across the five 
SNPs, according to the following formula:  
wGRSi = wjXij
j=1
5
∑  
where i is an individual, wGRSi is the wGRS for the individual i, j is a SNP, wj is the weight for 
the SNP j, and Xij is the number of risk alleles for the individual i and for the SNP j. Note that Xij 
takes the value 0, 1, or 2 for directly genotyped SNPs, and takes a continuous value ranging from 
0 to 2 for imputed SNPs. The weights for the five variants were estimated from the derivation 
samples (Supplementary Table IV). 
 
Derivation of a polygenic risk score  
  3 
Based on the derivation datasets that had been subjected to the quality control filters, the 
polyGRS was derived via two steps: (i) restricted maximum likelihood (REML) and (ii) best 
linear unbiased prediction (BLUP). In both steps, we assumed the following mixed linear model 
(MLM)4,6: 
yi = µ + gi + ei , 
where yi represents the dichotomous disease status (yi = 0: no disease; yi = 1: diseased status) of 
the i-th individual, µ  is the proportion of the cases in derivation samples, and gi and ei are 
normally distributed random variables representing genetic and nongenetic effects, respectively, 
i.e., gi ~ N(0,σ g2A)  and ei ~ N(0,σ e2I) , where A is a genetic relationship matrix (GRM), I is the 
identity matrix, and σ g
2  and σ e
2  are the variances of genetic and nongenetic effects, respectively. 
The GRM was calculated from SNP data as: 
A(i, j) = 1M
(xik − 2pk )(x jk − 2pk )
2pk (1− pk )k
∑ ,  
where M represents the number of SNPs after quality control filterings, xik is the genotype (0, 1, 
or 2) of the i-th individual and k-th SNP, and pk is the allele frequency of the k-th SNP. Estimates 
of σ g
2  and σ e
2  (denoted as σˆ g
2  and σˆ e
2 , respectively) were determined by solving the REML 
equation with the average information (AI-REML) algorithm.7,8 To avoid inflation of the 
estimate of σ g
2 , we included the top 20 principal components (PCs) as covariates of the above 
MLM.  
Given the REML estimates of σˆ g
2  and σˆ e
2 , the BLUP method calculates the genetic effect 
gˆ ,9 where gˆ  represents the N-dimensional vector of the estimates of genetic effects, and N is the 
number of individuals in the derivation dataset. The weight parameters for the 357,367 
genotyped variants uˆ  (the M-dimensional vector) were calculated from estimates of genetic 
effects gˆ and genotype data of the derivation dataset by the equation: uˆ = 1NWt
'A−1gˆ . 
Here, Wt  is the genotype data of the derivation dataset (N × M-dimensional matrix), which was 
normalized so that the average and standard deviation of the column vectors became 0 and 1, 
respectively. Wt'  represents the transposition of the matrix Wt .  
Note that the MLM takes into account genotype data via the GRM, and only the variance 
parameters, σ g
2  and σ e
2 , were free parameters in the MLM. The REML step estimates the two 
free parameters based on derivation samples (N = 39,684). In the BLUP step, no parameters were 
estimated. The BLUP step converts the estimates of the variance parameters (σˆ g
2  and σˆ e
2 ) into 
the weight parameters for the 357,367 SNPs in conjunction with the information of genotype 
data of derivation samples (A, and Wt ). In total, only two parameters were estimated through the 
REML and BLUP steps. This mathematical technique is called a ‘dual formula’, or ‘kernel 
trick’.10 
Based on the weight parameters uˆ , the polyGRS was calculated by multiplying the number 
of risk alleles for each SNP by the weight for that SNP, and then taking the sum across the 
357,367 SNPs, according to the following equation:  
  4 
polyGRSi = wjXij
j=1
357,367
∑  
 
Subtype-specific model 
The polyGRS was used in the subtype-specific models with 639 cases and 26,470 controls in the 
LVD-specific model, 2,214 cases and 26,470 controls in the SVD-specific model, and 310 cases 
and 26,470 controls in the CE-specific model as training dataset for each IS subtype. 
 
Score-profiling model 
Of the 537,999 genotyped SNPs, variants with an associated P value lower than a given PT 
threshold were included in the model. Coefficients (β) for the variants estimated from the MLM 
association method were used as model parameters. Let xik be the genotype (0, 1, or 2) of the i-th 
individual and k-th SNP, Pk the P value for the k-th SNP and βk  the coefficients for the k-th SNP. 
Then, the score-profiling-based genetic risk score of the i-th validation subjects could be 
calculated as follows: 
GRSiscore−profiling(PT ) = βk xk
k|Pk<PT
∑ . 
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Supplementary Table I. Association signals for six well-studied SNPs in derivation samples 
SNP Chr Candidate gene(s) RA
a RAF Rsq Pe 
ORf 
(95% CI) PMID 
rs2107595 7 HDAC9 Ab 0.35 0.98 0.02 1.03 (0.99–1.07) 
26089329, 
25031287, 
23041239 
rs6843082 4 PITX2 Gb 0.68 0.99 3.8 × 10-4 1.09 (1.04–1.13) 
26089329, 
25031287, 
23041239 
rs879324 16 ZFHX3 Ab 0.40 1.00d 0.04 1.06 (1.02–1.10) 
26089329, 
25031287, 
23041239 
rs2383207 9 CDKN2B, CDKN2A G
b 0.65 1.00d 6.2 × 10-4 1.08 (1.04–1.12) 
22306652, 
26089329, 
23041239 
rs11833579 12 NINJ2 Gc 0.57 0.96 0.12 1.04 (1.00–1.08) 
19369658, 
22306652, 
26089329, 
23041239 
rs2230500 14 PRKCH Gc 0.78 1.00 0.60 1.01 (0.97–1.06) 
17206144, 
23041239 
SNP indicates single nucleotide polymorphism; Chr, chromosome; RA, risk allele; RAF, risk 
allele frequency; Rsq, R-squared value of the locus imputation quality; OR, odds ratio; and CI, 
confidence interval; PMID, PubMed ID. 
aThe risk allele was determined based on our derivation samples. bThe direction of the effects 
was consistent with previous studies. cThe direction of the effects was inconsistent with previous 
studies. dThese variants were directory genotyped using the SNP array. eP-values were calculated 
by a mixed linear model association method. fORs were calculated from a logistic regression 
analysis.  
Results listed in bold are nominally significant (P < 0.05). 
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Supplementary Table II. Association signals for 30 recently reported SNPs in derivation 
samples 
SNP Chr Candidate gene RA
a RAF Rsq Pc 
ORd 
 (95% CI)  PMID 
rs225132 1 ERRFI1  T 0.44 1.00b 0.53 1.00 (0.96–1.03) 23041239 
rs1937787 1 ELTD1  C 0.08 1.00b 0.11 1.02 (0.96–1.09) 26089329 
rs11681884 2 
IL1RN, 
IL1F10, 
IL36RN  
C 0.78 1.00 0.88 0.97 (0.93–1.02) 26089329 
rs16851055 3 SPSB4 G 0.81 0.99b 0.42 1.03 (0.99–1.08) 23041239 
rs6763538 3 OXNAD1 C 0.96 1.00 0.12 1.12 (1.03–1.23) 23041239 
rs7432308 3 SATB1, KCNH8 T 0.25 0.99 0.64 
1.05 
(1.01–1.10) 23041239 
rs2930144 3 SLC6A11  C 0.14 0.99 0.47 1.06 (1.00–1.11) 25031287 
rs704341 3 PTPRG  G 0.98 0.73 0.07 1.06 (0.91–1.23) 26089329 
rs17007400 4 ILI5  G 0.01 0.94 0.61 1.10 (0.93–1.29) 25031287 
rs12646447 4 PITX2  C 0.45 0.98 0.06 1.05 (1.01–1.09) 
26089329, 
25031287 
rs7705819 5 MSX2, NKX2-5  T 0.44 0.65 0.38 
0.99 
(0.95–1.04) 26089329 
rs4867766 5 SUMO2P6, GAPDHP71 A 0.12 0.99 0.21 
1.00 
(0.95–1.06) 26089329 
rs556621 6 CDC5L,  SUPT3H T 0.59 1.00
b 0.55 1.04 (1.00–1.08) 
26089329, 
22941190, 
23041239 
rs9345396 6 TSG1  T 0.22 0.99 0.86 1.01 (0.96–1.06) 26089329 
rs17347800 7 HDAC9 G 0.87 1.00b 0.30 1.01 (0.95–1.06) 26089329 
rs4875812 8 ARHGEF10 G 0.64 0.89 0.75 1.02 (0.98–1.07) 23041239 
rs2281673 10 PLEKHA1  T 0.83 0.98 0.75 1.01 (0.96–1.06) 25031287 
rs7937106 11 SPSB4  C 0.08 1.00b 0.12 1.06 (0.99–1.13) 23041239 
rs2084637 11 UBASH3B  T 0.67 0.92 0.22 1.05 (1.01–1.09) 26089329 
rs2238151 12 ALDH2 T 0.07 1.00b 0.46 0.96 (0.90–1.04) 23041239 
rs10744777 12 ALDH2  T 0.07 1.00b 0.46 0.96 (0.90–1.04) 25031287 
rs4597201 13 NDF1P2  C 0.24 1.00 0.49 1.02 (0.98–1.07) 25031287 
rs10400694 14 – C 0.59 1.00 0.99 1.01 (0.97–1.05) 26089329 
rs7156510 14 FLRT2  T 0.58 0.98 0.83 1.01 (0.98–1.05) 26089329 
rs1564060 14 – G 0.64 0.98 0.30 1.02 26089329 
  7 
(0.98–1.06) 
rs4471613 15 ALDH1A2 A 0.04 0.97 0.62 1.11 (1.01–1.22) 26089329 
rs7407640 18 AFG3L2  A 0.41 1.00 0.88 1.00 (0.96–1.03) 23041239 
rs8113518 19 KRTDAP  T 0.73 1.00 0.59 1.02 (0.98–1.06) 25031287 
rs5752326 22 HPS4  T 0.85 1.00b 0.49 1.03 (0.98–1.09) 26089329 
SNP indicates single nucleotide polymorphism; Chr, chromosome; RA, risk allele; RAF, risk 
allele frequency; Rsq, R-squared value of the imputation quality on the locus; OR, odds ratio; and 
CI, confidence interval; PMID, PubMed ID. 
aThe risk allele was determined based on our derivation samples. bThese variants were directory 
genotyped using the SNP array. cP-values were calculated by a mixed linear model association 
method. dORs were calculated from a logistic regression analysis.  
Results listed in bold are nominally significant (P < 0.05).  
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Supplementary Table III. Novel association signals discovered from derivation samples 
with a suggested significance level (P < 1 × 10-5) 
SNP Chr Candidate gene(s) RA RAF Rsq P
a OR
b 
 (95% CI) 
rs1275923 2 KCNK3 C 0.75 0.86 4.8 × 10-8 1.15 (1.10–1.21) 
rs149493746 1 SFPQ, ZMYM4 G 0.07 0.81 1.0 × 10
-6 1.24 (1.15–1.34) 
rs142873372 1 ERI3, RNF220 C 0.01 0.51 2.4 × 10
-7 1.72 (1.40–2.12) 
rs203801 1 ADCY10 A 0.16 0.96 4.0 × 10-6 1.18 (1.12–1.24) 
rs13014165 2 INSIG2, EN1 T 0.15 0.97 1.4 × 10
-6 1.14 (1.08–1.20) 
rs788159 2 METAP1D, DLX1 G 0.70 1.00
c 1.3 × 10-6 1.12 (1.08–1.17) 
rs3774430 3 CACNA1D G 0.09 0.99 3.0 × 10-7 1.24 (1.16–1.32) 
rs814778 5 ADAMTS16 G 0.43 0.93 7.4 × 10-6 1.11 (1.06–1.15) 
rs150112040 5 PRLR C 0.82 0.88 7.8 × 10-6 1.15 (1.09–1.21) 
rs3783923 14 ITPK1 C 0.11 0.98 3.4 × 10-6 1.20 (1.13–1.27) 
rs140161480 15 NEO1,  HCN4 A 0.95 0.96 8.4 × 10
-6 1.14 (1.05–1.25) 
rs2047221 15 PCSK6 A 0.40 0.96 2.5 × 10-6 1.11 (1.07–1.15) 
rs144695373 17 KCNJ2,  CASC17 A 0.02 0.54 5.7 × 10
-6 1.47 (1.23–1.76) 
rs7222752 17 NTPX1,  RPTOR G 0.03 0.54 3.2 × 10
-6 1.49 (1.30–1.71) 
rs4371240 18 WDR7, LINC-ROR C 0.89 0.98 4.9 × 10
-6 1.18 (1.11–1.25) 
SNP indicates single nucleotide polymorphism; Chr, chromosome; RA, risk allele; RAF, risk 
allele frequency; Rsq, R-squared value of the imputation quality; OR, odds ratio; and CI, 
confidence interval.  
aP-values were calculated by a mixed linear model association method. bORs were calculated 
from a logistic regression analysis.  
Results listed in bold are genome-wide significance (P < 5 × 10-8).
  9 
Supplementary Table IV. Weight parameters for our multi-locus genetic risk score 
SNP Chr Candidate gene(s) RA 
Weight 
per allelea 
Derivation 
 (N = 39,684)  
KyushuU 
 (N = 2,194)  
JPJM 
(N = 672) 
OR 
(95% CI)b P
c  OR (95% CI)b P
d  OR (95% CI)b P
d 
rs2107595 7 HDAC9 A 0.00662955 1.03 (0.99–1.07) 0.02   
1.13 
(1.00–1.28) 0.05   
0.82 
(0.66–1.01) 0.06 
rs6843082 4 PITX2 G 0.01113360 1.09 (1.04–1.13) 3.8 × 10
-4   1.04 (0.92–1.17) 0.57   
1.05 
(0.85–1.30) 0.63 
rs879324 16 ZFHX3 A 0.00601980 1.06 (1.02–1.10) 0.04  
1.03 
(0.92–1.16) 0.61  
1.04 
(0.84–1.28) 0.71 
rs2383207 9 CDKN2B, CDKN2A G 0.01047050 
1.08 
(1.04–1.12) 6.2 × 10
-4   1.03 (0.91–1.17) 0.61   
1.03 
(0.83–1.29) 0.78 
rs1275923 2 KCNK3 C 0.01882280 1.15 (1.10–1.21) 4.8 × 10
-8  0.98 (0.85–1.14) 0.79  
1.35 
(1.03–1.76) 0.03 
SNP indicates single nucleotide polymorphism; Chr, chromosome; RA, risk allele; OR, odds ratio; and CI, confidence interval.  
aWeight parameters were estimated from the derivation samples. bORs were calculated by a linear regression analysis in the derivation 
samples. cP-values were calculated by a mixed linear model association analysis in the derivation samples. dP-values and ORs were 
calculated by a conditional logistic regression analysis in the KyushuU and JPJM samples.  
Results listed in bold are nominally significant (P < 0.05).  
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Supplementary Table V. Predictive ability of the polygenic risk scores with varying PT threshold in the KyushuU samples (N = 
2,194) 
PT #. SNPs 
Q1 OR 
(95% CI) 
Q2 OR 
(95% CI) 
Q3 OR 
(95% CI) 
Q4 OR 
(95% CI) 
Q5 OR 
(95% CI) 
OR per 1 SDa 
(95% CI) 
Overalla 
P-value 
C-index 
(95% CI) 
1.0 × 10-5 12 Reference 0.83 (0.63–1.09) 
1.03 
(0.79–1.34) 
1.10 
(0.84–1.45) 
0.82 
(0.63–1.08) 
0.95 
(0.87–1.03) 0.221 
0.506 
(0.482–0.530) 
1.0 × 10-4 49 Reference 0.77 (0.59–1.02) 
0.98 
(0.74–1.29) 
0.95 
(0.72–1.24) 
0.86 
(0.66–1.14) 
0.98 
(0.90–1.07) 0.655 
0.494 
(0.470 –0.518) 
0.001 565 Reference 0.89 (0.68–1.17) 
1.05 
(0.80–1.38) 
1.27 
(0.96–1.67) 
1.09 
(0.83–1.43) 
1.07 
(0.98–1.16) 0.129 
0.522 
(0.498–0.546) 
0.01 5,304 Reference 1.57 (1.19–2.07) 
1.44 
(1.09–1.89) 
1.60 
(1.21–2.10) 
1.55 
(1.18–2.05) 
1.15 
(1.06–1.25) 0.001 
0.538 
(0.514–0.562) 
0.05 26,327 Reference 1.43 (1.09–1.88) 
1.24 
(0.94–1.63) 
1.20 
(0.91–1.58) 
1.73 
(1.32–2.28) 
1.15 
(1.06–1.25) 0.001 
0.538 
(0.514–0.562) 
0.1 52,910 Reference 1.07 (0.81–1.40) 
1.23 
(0.93–1.62) 
1.21 
(0.92–1.59) 
1.54 
(1.17–2.02) 
1.14 
(1.05–1.24) 0.003 
0.539 
(0.515–0.563) 
0.2 106,326 Reference 1.12 (0.85–1.47) 
1.13 
(0.86–1.49) 
1.22 
(0.93–1.61) 
1.58 
(1.20–2.08) 
1.15 
(1.06–1.25) 0.001 
0.543 
(0.519–0.567) 
0.5 268,120 Reference 1.21 (0.92–1.59) 
1.22 
(0.93–1.60) 
1.14 
(0.86–1.50) 
1.75 
(1.33–2.31) 
1.17 
(1.08–1.27) <0.001 
0.545 
(0.521–0.569) 
1.0 537,999 Reference 1.23 (0.94–1.62) 
1.32 
(1.00–1.74) 
1.09 
(0.83–1.43) 
1.82 
(1.38–2.40) 
1.17 
(1.08–1.27) <0.001 
0.546 
(0.522–0.570) 
SNP indicates single nucleotide polymorphism; OR indicates odds ratio; CI, confidence interval; and Q1–Q5, quantiles 1–5.  
aConsidering the genetic risk scores as continuous variables.  
Results listed in bold are nominally significant (P < 0.05). 
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Supplementary Table VI. Improvement in predictive ability by substituting the multi-locus genetic risk score with the 
polygenic risk score in the KyushuU and JPJM samples 
Validation 
samples Subtype NRI (95% CI) IDI (95% CI) ∆C-index 
KyushuU all IS N = 2,194 
0.179 (0.095–0.262) 
P < 0.001*  
0.008 (0.004–0.012) 
P < 0.001* 
0.045 
P = 0.007* 
  LVD N = 720 
0.206 (0.060–0.351) 
P = 0.006 
0.013 (0.004–0.021) 
P = 0.004 
0.054 
P = 0.066 
 SVD N = 972 
0.185 (0.060–0.310) 
P = 0.003 
0.007 (0.002–0.012) 
P = 0.011 
0.049 
P = 0.044 
  CE N = 268 
0.194 (-0.044–0.432) 
P = 0.110 
0.015 (0.000–0.030) 
P = 0.056 
0.053 
P = 0.250 
JPJM all IS N = 672 
0.071 (-0.080–0.223) 
P = 0.354 
0.003 (-0.004–0.010) 
P = 0.384 
0.006 
P = 0.854 
NRI indicates net reclassification improvement; IDI, integrated discrimination improvement; CI, confidence interval; IS, ischemic 
stroke; LVD, large-vessel disease; SVD, small-vessel disease; and CE, cardioembolic stroke. 
Results listed in bold are nominally significant (P < 0.05).  
*Significant after multiple corrections.
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Supplementary Table VII. Predictive ability of the multi-locus and the polygenic risk scores for each etiological subtype in the 
KyushuU samples 
Subtype Model Q1 OR (95% CI) 
Q2 OR 
(95% CI) 
Q3 OR 
(95% CI) 
Q4 OR 
(95% CI) 
Q5 OR 
(95% CI) 
OR per 1 SDa 
(95% CI) 
Overalla 
P-value 
C-index 
(95% CI) 
LVD 
N = 720 wGRS Reference 
0.87 
(0.53–1.42) 
1.12 
(0.69–1.82) 
0.85 
(0.52–1.38) 
1.21 
(0.75–1.98) 
1.06 
(0.92–1.23) 0.434 
0.514 
(0.472–0.556) 
 
polyGRS 
(subtype-
mixture) 
Reference 1.25 (0.77–2.05) 
1.18 
(0.72–1.94) 
1.65 
(1.01–2.71) 
2.19 
(1.34–3.62) 
1.26 
(1.09–1.47) 0.002 
0.568 
(0.527–0.610) 
 
polyGRS 
(subtype-
specific) 
Reference 1.18 (0.72–1.93) 
0.97 
(0.60–1.59) 
1.21 
(0.75–1.98) 
1.25 
(0.77–2.04) 
1.08 
(0.93–1.26) 0.302 
0.522 
(0.479–0.564) 
SVD 
N = 972 wGRS Reference 
1.22 
(0.80–1.85) 
1.01 
(0.67–1.53) 
1.05 
(0.69–1.60) 
1.11 
(0.73–1.68) 
1.00 
(0.89–1.14) 0.944 
0.501 
(0.465–0.537) 
 
polyGRS 
(subtype-
mixture) 
Reference 0.91 (0.60–1.38) 
1.14 
(0.75–1.74) 
1.29 
(0.85–1.96) 
1.61 
(1.06–2.45) 
1.18 
(1.04–1.34) 0.012 
0.550 
(0.514–0.586) 
 
polyGRS 
(subtype-
specific) 
Reference 0.89 (0.59–1.36) 
0.91 
(0.60–1.38) 
1.14 
(0.75–1.74) 
1.25 
(0.83–1.90) 
1.09 
(0.96–1.23) 0.197 
0.526 
(0.490–0.562) 
CE 
N = 268 wGRS Reference 
1.40 
(0.61–3.22) 
1.45 
(0.64–3.32) 
1.50 
(0.66–3.47) 
1.45 
(0.64–3.32) 
1.08 
(0.85–1.37) 0.542 
0.527 
(0.458–0.597) 
 
polyGRS 
(subtype-
mixture) 
Reference 1.89 (0.82–4.43) 
1.26 
(0.54–2.93) 
2.38 
(1.03–5.61) 
2.45 
(1.06–5.77) 
1.28 
(1.00–1.62) 0.047 
0.580 
(0.512–0.649) 
 
polyGRS 
(subtype-
specific) 
Reference 0.89 (0.39–2.04) 
1.44 
(0.64–3.31) 
2.06 
(0.89–4.85) 
0.80 
(0.35–1.83) 
0.94 
(0.75–1.18) 0.601 
0.492 
(0.422–0.562) 
OR indicates odds ratio; CI, confidence interval; SD, standard deviation; wGRS, weighted multi-locus genetic risk score; polyGRS, 
polygenic risk score; IS, ischemic stroke; LVD, large-vessel disease; SVD, small-vessel disease; CE, cardioembolic stroke; and Q1–
Q5, quantiles 1–5.  
aConsidering the genetic risk scores as continuous variables.  
Results listed in bold are nominally significant (P < 0.05). 
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Supplementary Table VIII. Improvement in predictive ability gained by adding the multi-locus or polygenic risk scores to a 
non-genetic risk model in the KyushuU samples (N = 2,194) 
Subtype 
C-index 
without GRSa 
(95% CI) 
Model NRI (95% CI) 
IDI 
(95% CI) 
C-index 
with GRSb 
(95% CI) 
∆C-index 
all IS 
N = 2,194 
0.694 
(0.672–0.715) wGRS 
-0.011 (-0.095–0.073) 
P = 0.797 
0.000 (0.000–0.001) 
P = 0.479 
0.695 
(0.673–0.717) 
0.001 
P = 0.487 
  polyGRS (PT = 1) 
0.075 (-0.009–0.158) 
P = 0.080 
0.004 (0.001–0.006) 
P = 0.004 
0.700 
(0.679–0.722) 
0.007 
P = 0.067 
    polyGRS G-BLUP 
0.151 (0.068–0.235) 
P < 0.001 
0.004 (0.001–0.006) 
P = 0.003 
0.700 
(0.679–0.722) 
0.007 
P = 0.080 
LVD 
N = 720 
0.696 
(0.659–0.734) wGRS 
0.017 (-0.129–0.163) 
P = 0.823 
0.001 (-0.001–0.002) 
P = 0.629 
0.701 
(0.663–0.739) 
0.005 
P = 0.156 
  polyGRS (PT = 1) 
-0.022 (-0.168–0.124) 
P = 0.766 
0.002 (-0.001–0.006) 
P = 0.178 
0.702 
(0.664–0.740) 
0.006 
P = 0.131 
    polyGRS G-BLUP 
0.200 (0.055–0.345) 
P = 0.007 
0.007 (0.001–0.012) 
P = 0.026 
0.707 
(0.669–0.745) 
0.011 
P = 0.045 
SVD 
N = 972 
0.675 
(0.642–0.709) wGRS 
0.029 (-0.097–0.154) 
P = 0.653 
0.000 (0.000–0.000) 
P = 0.980 
0.676 
(0.642–0.710) 
0.001 
P = 0.846 
  polyGRS (PT = 1) 
0.128 (0.002–0.253) 
P = 0.046 
0.007 (0.001–0.012) 
P = 0.014 
0.687 
(0.654–0.721) 
0.012 
P = 0.262 
    polyGRS G-BLUP 
0.185 (0.060–0.310) 
P = 0.004 
0.004 (0.000–0.009) 
P = 0.047 
0.688 
(0.654–0.721) 
0.012 
P = 0.214 
CE 
N = 268 
0.917 
(0.881–0.953) wGRS 
0.254 (0.017–0.490) 
P = 0.035 
0.002 (-0.003–0.008) 
P = 0.421 
0.922 
(0.886–0.957) 
0.004 
P = 0.539 
  polyGRS (PT = 1) 
-0.015 (-0.254–0.224) 
P = 0.903 
0.000 (-0.002–0.002) 
P = 0.651 
0.920 
(0.885–0.956) 
0.003 
P = 0.527 
    polyGRS G-BLUP 
0.015 (-0.224–0.254) 
P = 0.903 
0.000 (0.000–0.000) 
P = 0.943 
0.918 
(0.882–0.954) 
0.000 
P = 0.883 
GRS indicates genetic risk score; IS, ischemic stroke; LVD, large-vessel disease; SVD, small-vessel disease; CE, cardioembolic 
stroke; NRI, net reclassification improvement; IDI, integrated discrimination improvement; and CI, confidence interval.  
aA non-genetic risk model, which includes hypertension, diabetes mellitus, hyperlipidemia, and atrial fibrillation as model variables. 
bAn integrated risk model, which includes hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, and a genetic risk score 
as model variables.  
Results listed in bold are nominally significant (P < 0.05).  
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Supplementary Figure I. Genome-wide association signals from the Japanese derivation samples. 
The x-axis represents chromosomal positions and the y-axis represents –log10 P-values calculated by a 
mixed linear model association analysis. The red and blue horizontal lines indicate the genome-wide 
significance level (P = 5 × 10-8) and the suggestive significance level (P = 1 × 10-5), respectively. 
Candidate genes near genome-wide and suggestive signals are shown in red and blue, respectively.  
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Supplementary Figure II. Association signals around the KCNK3 gene. The x-axis represents 
chromosomal positions near the KCNK3 gene, and the y-axis represents –log10 P-values. The top signal 
in this locus (rs1275923) is shown in purple. Dot color for a variant represents the degree of 
linkage disequilibrium (R2) estimates between the variant and rs1275923. In this region, a variant 
(rs1275988) related to blood pressure was harbored. The rs1275988 variant, shown in red, is apart from 
~18,000 base-pairs from the rs1275923 variant. The rs1275923 and rs1275988 variants were located 
within the same linkage disequilibrium block.  
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Supplementary Figure III. Predictive ability improvement by substituting the multi-locus genetic risk 
score with the polygenic risk score in the KyushuU and JPJM samples. NRI indicates net 
reclassification improvement; IS, ischemic stroke; LVD, large-vessel disease; SVD, small-vessel 
disease; and CE, cardioembolic stroke. Nominal significant differences (P < 0.05) are indicated with 
asterisks. Significant difference after multiple corrections is indicated with double-asterisk.
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Supplementary Figure IV. A quantile-quantile plot of the P-values from the genome-wide association 
tests. The x-axis indicates the expected -log10 P-values under the null hypothesis. The y-axis shows 
the observed -log10 P-values calculated by a mixed linear model association method.7 The grey line 
represents y = x, which corresponds to the null hypothesis. λGC  (the inflation factor of the genomic 
control method) is the median of the observed test statistics divided by the median of the expected test 
statistics.  
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